Thursday, January 6, 2011

Platinum and Blue Light Combine to Combat Cancer...

Research led by the University of Warwick, along with researchers from Ninewells Hospital Dundee, and the University of Edinburgh, have found a new light-activated platinum-based compound that is up to 80 times more powerful than other platinum-based anti-cancer drugs and which can use “light activation” to kill cancer cells in a much more targeted way than similar treatments. 

The University of Warwick team had already found a platinum-based compound that they could activate with ultra-violet light but that narrow wave length of light would have limited its use. Their latest breakthrough has discovered a new platinum based compound known as trans,trans,trans-[Pt(N3)2(OH)2(py)2] (see structure)  that can be activated by normal visible blue, or even green, light. It is also stable and easy to work with, and it is water soluble so it can simply dissolve and be flushed out of the body after use. Tests show that once activated by blue light the compound was highly effective requiring a concentration of just 8.4 micro moles per litre to kill 50% of the cancer cells. The researchers are also beginning to examine the compound’s effectiveness against ovarian and liver cancer cells. Early results there are also excellent but that testing work is not yet complete.

“This compound could have a significant impact on the effectiveness of future cancer treatments. Light activation provides this compound’s massive toxic power and also allows treatment to be targeted much more accurately against cancer cells...claims Prof.  Peter Sadler...

Ref : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2980786/

Saturday, January 1, 2011

Ginseng just got better -- not as bitter

Ginseng just got better -- not as bitter

HAPPY NEW YEAR - 2011

WISHING ONE AND ALL "A HAPPY,  PROSPEROUS AND PEACEFUL NEW YEAR-2011.

Tuesday, December 28, 2010

Almonds can help treat, prevent type 2 diabetes and cardiovascular disease

We know that the sweet almond contains about 26% carbohydrates (12% dietary fiber, 6.3% sugars, 0.7% starch and the rest miscellaneous carbohydrates), and may therefore be made into flour for cakes and cookies (biscuits) for low-carbohydrate diets or for patients suffering from diabetes mellitus or any other form of glycosuria.

Now the same has been further substantiated by the researchers from Nutrition at Loma Linda University's School of Public Health and Principal Investigator for this study, which was conducted at the University of Medicine and Dentistry of New Jersey.

The study looked at the effects of consuming an almond-enriched diet as it relates to the progression of type 2 diabetes and cardiovascular disease in adults with pre-diabetes. After 16 weeks of consuming either an almond-enriched or regular diet, both of which conformed with American Diabetes Association (ADA) recommendations, the group that consumed an almond-enriched diet showed significantly improved LDL cholesterol levels and measures of insulin sensitivity, risk factors for heart disease and type 2 diabetes.

Researchers conclude that, overall, consuming an ADA-recommended diet consisting of 20% of the total calories from almonds for 16 weeks is effective in improving LDL cholesterol levels and measures of insulin sensitivity in individuals with pre-diabetes. Nutrients in almonds, such as fiber and unsaturated fat, have been shown to help maintain healthy cholesterol levels and increase insulin sensitivity, both of which help to prevent the development of type 2 diabetes and reduce the risk of cardiovascular disease.   It also provides evidence that suggests almonds contribute to heart health. However, it adds a new dimension to the existing research because it shows almond consumption not only aids in disease management, but may also help reduce the risk  of certain chronic diseases. Almonds offer 3.5 grams of fiber, 13 grams of unsaturated fat and only 1 gram of saturated fat per one-ounce serving.

Ref : http://www.almondboard.com/InTheNews/Pages/ArticleDetails.aspx?aID=97

Thursday, December 23, 2010

Wednesday, December 22, 2010

Researchers demonstrate that monensin antibiotic prevents prostate cancer cell growth

We know that, monensin was first described by Agtarap et al. in 1967, and was the first polyether antibiotic to have its structure elucidated in this way. The first total synthesis of monensin was reported in 1979 by Kishi et al. 

Researchers from VTT Technical Research Centre of Finland and the University of Turku have demonstrated that  "monensin" prevents the growth of prostate cancer cells. 

Evidence pointing to the effects of monensin emerged in a project investigating the effects of nearly 5,000 drugs and micromolecules on the growth of prostate cancer cells. The project involved most of the drugs on the market today. Researchers found that small amounts of compounds - disulfiram (Antabus), thiram, tricostatin A, and monensin (see structure) - can prevent the growth of prostate cancer cells without significant effects on the growth of the normal human prostate epithelial cells.  Further studies revealed that monensin caused prostate cancer cell death by reducing the amount of testosterone receptor and by increasing production of reactive oxygen species and inducing DNA damage. In addition, monensin was shown to have combined effects with anti-androgens - the drugs suppressing the effects of androgens - in preventing prostate cancer cell growth. 

"These research findings give rise to a potential new use for the monensin. The results also demonstrate that the effects of anti-androgens in suppressing the growth of cancer cells can be enhanced by using drugs inducing production of reactive oxygen species", say Senior Research Scientist Kristiina Iljin from VTT and Research Scientist Kirsi Ketola from the University of Turku....

Ref : http://www.vtt.fi/index.jsp
http://www.vtt.fi/news/2011/topicals/20111208_eturauhassyovanesto.jsp?lang=fi

Monday, December 20, 2010

Boceprevir drug may cure hepatitis C

In continuation of my update on Boceprevir
Boceprevir drug may cure hepatitis C

Sunday, December 19, 2010

Compound derived from curry spice is neuroprotective against stroke and traumatic brain injury


A synthetic derivative of the curry spice turmeric, made by scientists at the Salk Institute for Biological Studies, dramatically improves the behavioral and molecular deficits seen in animal models of ischemic stroke and traumatic brain injury (TBI). Two new studies suggest that the novel compound may have clinical promise for these conditions, which currently lack good therapies.

In earlier studies, David R. Schubert, Ph.D., and Pamela Maher, Ph.D., in the Salk Cellular Neurobiology Laboratory had developed a series of new compounds using a novel drug discovery paradigm that starts with natural products derived from plants; it then calls for selecting synthetic derivatives that show efficacy in multiple assays testing protection against various aspects of the nerve cell damage and death that occur in brain injuries and in age-associated neurodegenerative diseases. One compound, called CNB-001, which was derived from curcumin, the active ingredient in the spice turmeric, proved highly neuroprotective in all of the assays; it also enhanced memory in normal animals.... 

Goji berries' components are available in fruits and vegetables

Goji berries' components are available in fruits and vegetables

Friday, December 17, 2010

Soy isoflavone intake decreases risk of invasive breast tumor.....

                                             

Genistein                                                                          Daidzein

Increased phytoestrogens commonly found in dietary soy may modify the risk of some types of breast cancer, according to findings presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held Nov. 7-10, 2010.

Anne Weaver and colleagues evaluated 683 women with breast cancer and compared them with 611 healthy women. Dietary data patterns were observed using a food frequency questionnaire and isoflavones were measured as a dietary, rather than supplemental, intake. Isoflavone (as for as my knowledge goes, above two isoflavones- see structures are present in soya) intake was divided into three groups. Those women with the highest isoflavone intake had an approximately 30 percent decreased risk of having an invasive breast tumor, and an approximately 60 percent decreased risk of having a grade 1 tumor. Among premenopausal women, the highest intake of isoflavones had a 30 percent decreased risk of stage I disease, a 70 percent decreased risk of having a tumor larger than 2 cm, and a 60 percent decreased risk of having stage 2 breast cancer. These connections were not seen among postmenopausal women...

Ref : http://www.buffalo.edu/news/fast-execute.cgi/article-page.html?article=120510009